Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Painless patch could replace finger pricks for glucose and ketone monitoring

NCT ID NCT06977633

Knowledge-focused Sponsor: Mahla Poudineh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new device: a small patch with tiny, painless needles that sits on the skin and measures glucose and ketone levels continuously. Ten people with type 1 diabetes will wear the patch for 4 hours while briefly stopping their insulin pumps. Researchers will compare the patch's readings to standard blood tests to see how accurate it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glucose and ketone sensor (prototype device)
What this could lead to
If successful, this could lead to a painless, continuous way to monitor both glucose and ketones, helping people with type 1 diabetes manage their condition more easily.
What could go wrong
This is a very small, early pilot study with only 10 participants. The sensor is tested for just 4 hours, so it may not work reliably over longer periods or in real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of type 1 diabetes for at least 1 year without significant endogenous insulin production * Currently using insulin pump * Understanding and willingness to follow the protocol and sign informed consent. * Willingness to sign a consent for release of medical information at the time of enrollment * Ability to speak, read and write in the language of the investigators. Exclusion Criteria: * History of DKA or severe hypoglycemia within the past 6 months * eGFR \<45 mL/min/1.73 m2 or other significant renal impairment * Pregnancy or breastfeeding * Current use of non-insulin medications affecting ketone production, including SGLT2 inhibitors * Active skin infections or conditions affecting sensor application sites * Known skin allergies to tapes or adhesives * Current use of any long-acting insulin analogs * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes (T1D) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes (T1D)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Stanford University

    Palo Alto, California, 94304, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.